InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (9 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
9
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Goldan Keith A., Chief Financial Officer. Director active across 4 companies, notably OptiNose, Inc.. Cumulatively, 17 reports have been published. Split: 2 buys · 9 sells. Total volume traded: €109k. History available since 17 June 2021. The latest transaction was filed on 1 April 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations17 total
32,751 shares0Common StockSEC:0001493152-26-015456:0
3,000 sharesCommon StockSEC:0000950170-25-074304:0
Ideal exit: 13 Feb 2026 (T+270)
3,777 shares@ US$15.50453.5% of flowCommon StockSEC:0000950170-25-019005:0
18,500 shares0Common StockSEC:0000950170-25-016389:0
1,250 shares@ US$20.029821.9% of flowCommon StockSEC:0001562180-24-005118:0
Ideal exit: 11 Mar 2025 (T+270)
862 shares@ US$18.1213.4% of flowCommon StockSEC:0001562180-24-001222:0
577 shares@ US$22.3111.2% of flowCommon StockSEC:0001562180-23-005152:0
3,205 shares0Common StockSEC:0001562180-22-005117:0
4,617 shares@ US$2.1152.5% of flowCommon StockSEC:0001494650-22-000029:0
56,730 shares0Common StockSEC:0001494650-22-000006
56,730 shares0Common StockSEC:0001494650-22-000006:0
580 shares@ US$1.645.0% of flowCommon StockSEC:0001494650-21-000155
580 shares@ US$1.645.0% of flowCommon StockSEC:0001494650-21-000155:0
578 shares@ US$2.7898.1% of flowCommon StockSEC:0001494650-21-000108:0
578 shares@ US$2.7898.1% of flowCommon StockSEC:0001494650-21-000108
576 shares@ US$3.7310.7% of flowCommon StockSEC:0001494650-21-000076
576 shares@ US$3.7310.7% of flowCommon StockSEC:0001494650-21-000076:0
17 of 17 declarations
About Goldan Keith A.
Keith A. Goldan is the Chief Financial Officer of OptiNose, Inc. and Syndax Pharmaceuticals Inc. In this role, he is responsible for the financial management of both companies, including planning and financial reporting. His expertise in finance is crucial for the growth of these companies.
